PAVmed

PAVmed Book Value per Share

The Book Value per Share of PAVmed (PAVM) as of Oct 21, 2026 is 33.97 USD. In the previous year, Book Value per Share was -2.50 USD — a change of -1,461.40% (higher).

Book Value per Share

33.97USD

YoY

-1,461.40%

Last updated:

Book Value per Share of PAVmed is 2025 33.97 USD. Book Value per Share of PAVmed was 2024 -2.50 USD. It decreases by -1,461.40% higher compared to the previous year.

The PAVmed Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
-2.31 USD
Jan 1, 2019
-3.82 USD
Jan 1, 2020
1.90 USD
Jan 1, 2021
61.67 USD
Jan 1, 2022
-9.68 USD
Jan 1, 2023
-53.83 USD
Jan 1, 2024
-2.50 USD
Jan 1, 2025
33.97 USD
The PAVmed Book Value per Share history
YEARBook Value per ShareYoY
33.97USD-1,461.40%
-2.50USD-95.37%
-53.83USD+456.05%
-9.68USD-115.70%
61.67USD+3,152.43%
1.90USD-149.58%
-3.82USD+65.20%
-2.31USD-18.74%
-2.85USD+792.71%
-0.32USD-150.33%
0.63USD-20.24%
0.79USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PAVmed stock

Book Value per Share of PAVmed is 33.97 USD in 2025.

Book Value per Share of PAVmed changed from -2.50 USD to 33.97 USD, representing a -1,461.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share PAVmed since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PAVmed

All Key Metrics — PAVmed